MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 531950 | Name: H2L5186303
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

H2L5186303 is a potent and selective lysophosphatidic acid 2 (LPA2) receptor antagonist (IC50 values are 8.9, 1230 and 27354 nM).

Chemical Structure

H2L5186303
H2L5186303
CAS#139262-76-3

Theoretical Analysis

MedKoo Cat#: 531950

Name: H2L5186303

CAS#: 139262-76-3

Chemical Formula: C26H20N2O8

Exact Mass: 488.1220

Molecular Weight: 488.45

Elemental Analysis: C, 63.93; H, 4.13; N, 5.74; O, 26.20

Price and Availability

Size Price Availability Quantity
5mg USD 125.00 Ready to ship
10mg USD 200.00 Ready to ship
25mg USD 350.00 Ready to ship
50mg USD 550.00 Ready to ship
100mg USD 950.00 Ready to ship
200mg USD 1,650.00 Ready to ship
500mg USD 3,450.00 Ready to ship
1g USD 5,250.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
H2L5186303; H2L 5186303; H2L-5186303.
IUPAC/Chemical Name
(2Z,2'Z)-4,4'-(((1,3-phenylenebis(oxy))bis(4,1-phenylene))bis(azanediyl))bis(4-oxobut-2-enoic acid)
InChi Key
HZFPOTBCYPWQSH-DZDAAMPGSA-N
InChi Code
InChI=1S/C26H20N2O8/c29-23(12-14-25(31)32)27-17-4-8-19(9-5-17)35-21-2-1-3-22(16-21)36-20-10-6-18(7-11-20)28-24(30)13-15-26(33)34/h1-16H,(H,27,29)(H,28,30)(H,31,32)(H,33,34)/b14-12-,15-13-
SMILES Code
O(C1=CC(OC2=CC=C(NC(/C=C\C(O)=O)=O)C=C2)=CC=C1)C3=CC=C(NC(/C=C\C(O)=O)=O)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
H2L5186303 is a selective lysophosphatidic acid 2 (LPA2) receptor antagonist (IC50 = 9 nM in a LPA-elicited calcium mobilization assay). It inhibits LPA1 and LPA3 at much higher concentrations (IC50s = 27,354 and 4,504 nM, respectively).
In vitro activity:
The high cell invasion activity of human fibrosarcoma HT1080-M6 cells was significantly suppressed by H2L5186303, suggesting that LPA2 acts as a key regulator of malignant properties in HT1080 cells. Reference: Biochem Biophys Res Commun. 2018 Sep 18;503(4):2698-2703. https://pubmed.ncbi.nlm.nih.gov/30093116/
In vivo activity:
H2L5186303 showed strong suppressive efficacy in a single experimental protocol of ovalbumin (OVA)-induced allergic asthma when administered before OVA sensitization and challenge, such as suppression of airway hyper responsiveness, inflammatory cytokine levels, mucin production, and eosinophil numbers. Reference: Int J Mol Sci. 2022 Aug 28;23(17):9745. https://pubmed.ncbi.nlm.nih.gov/36077141/
Solvent mg/mL mM
Solubility
DMSO 48.8 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 488.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Takahashi K, Minami K, Otagaki S, Ishimoto K, Fukushima K, Fukushima N, Honoki K, Tsujiuchi T. Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2698-2703. doi: 10.1016/j.bbrc.2018.08.026. Epub 2018 Aug 7. PMID: 30093116. 2. Olianas MC, Dedoni S, Onali P. LPA1 is a key mediator of intracellular signalling and neuroprotection triggered by tetracyclic antidepressants in hippocampal neurons. J Neurochem. 2017 Oct;143(2):183-197. doi: 10.1111/jnc.14150. Epub 2017 Sep 11. PMID: 28815598. 3. Lee YJ, Im DS. Efficacy Comparison of LPA2 Antagonist H2L5186303 and Agonist GRI977143 on Ovalbumin-Induced Allergic Asthma in BALB/c Mice. Int J Mol Sci. 2022 Aug 28;23(17):9745. doi: 10.3390/ijms23179745. PMID: 36077141; PMCID: PMC9456302.
In vitro protocol:
1. Takahashi K, Minami K, Otagaki S, Ishimoto K, Fukushima K, Fukushima N, Honoki K, Tsujiuchi T. Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2698-2703. doi: 10.1016/j.bbrc.2018.08.026. Epub 2018 Aug 7. PMID: 30093116. 2. Olianas MC, Dedoni S, Onali P. LPA1 is a key mediator of intracellular signalling and neuroprotection triggered by tetracyclic antidepressants in hippocampal neurons. J Neurochem. 2017 Oct;143(2):183-197. doi: 10.1111/jnc.14150. Epub 2017 Sep 11. PMID: 28815598.
In vivo protocol:
1. Lee YJ, Im DS. Efficacy Comparison of LPA2 Antagonist H2L5186303 and Agonist GRI977143 on Ovalbumin-Induced Allergic Asthma in BALB/c Mice. Int J Mol Sci. 2022 Aug 28;23(17):9745. doi: 10.3390/ijms23179745. PMID: 36077141; PMCID: PMC9456302.
1: Fells JI, Tsukahara R, Liu J, Tigyi G, Parrill AL. Structure-based drug design identifies novel LPA3 antagonists. Bioorg Med Chem. 2009 Nov 1;17(21):7457-64. doi: 10.1016/j.bmc.2009.09.022. PubMed PMID: 19800804; PubMed Central PMCID: PMC2771199.